Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2015 Archives

Dec 9, 2015

Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin...

More
Dec 2, 2015

Eisai Inc. announced today that 21 posters highlighting perampanel data and an interim analysis from the first and largest caregiver burden study in epilepsy will be presented at the 69th Annual...

More
Dec 1, 2015
Long-Term, Large-Scale Outcomes Study Assesses Cardiovascular and Metabolic Effects of BELVIQ in Overweight and Obese Patients

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight...

More
Nov 30, 2015

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended...

More
Nov 18, 2015
Clinical Study (MORAb-009-201) of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM)

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS—Amatuximab Research in Treatment-naïve Epithelial...

More
Nov 17, 2015

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to...

More
Nov 13, 2015

Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology...

More
Nov 9, 2015

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...

More
Nov 4, 2015
The parties hope to develop new cancer targets and novel therapeutic approaches

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC),...

More
Oct 26, 2015

Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...

More
Oct 26, 2015

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...

More
Oct 19, 2015
Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
Oct 16, 2015

Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...

More
Oct 15, 2015

Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...

More
Oct 8, 2015

Eisai Inc. announced the decision of the National Comprehensive Cancer Network® (NCCN®) to recommend LENVIMA™ (lenvatinib) as the preferred agent for the treatment of patients with progressive...

More
Sep 28, 2015

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for eribulin mesylate (eribulin) being evaluated...

More
Sep 24, 2015
Eisai, CancerCare®, Cancer Support Community®, Cornucopia Cancer Support Center™ and Meals on Wheels America Continue their Commitment to Providing Meal Assistance to Enable Loved Ones to Spend More Quality Time Together

Magnolia Meals at Home®, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now helping those living with thyroid cancer. Sponsored...

More
Sep 14, 2015

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for FYCOMPA® (perampanel) CIII Oral Suspension 0.5...

More
Aug 31, 2015
Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement for the development and...

More
Aug 24, 2015
Global Multicenter Study of FYCOMPA as Adjunctive Therapy Published in Neurology

Eisai Inc. announced today that the results of its Phase 3 trial (Study 332) for FYCOMPA® (perampanel) CIII have been published in the online edition of Neurology, the medical journal of the...

More
Jul 31, 2015
Clinical trial will explore whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San Diego,...

More
Jul 30, 2015

Eisai Inc. announced today that regulatory applications were submitted simultaneously in the United States, European Union and Japan (to the FDA, EMA and MHLW, respectively) for eribulin, for the...

More
Jul 28, 2015

Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the...

More
Jul 16, 2015
Deal Supports Strategic Directions of Both Companies and Expands Collaboration

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP)...

More
Jun 22, 2015
New Indication Provides a Treatment Option for Epilepsy Patients Who Suffer from PGTC Seizures that are not Adequately Controlled with Current Treatment

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic...

More
 

print email rss